| First Author | Shen L | Year | 2020 |
| Journal | Cancer Lett | Volume | 472 |
| Pages | 40-49 | PubMed ID | 31857155 |
| Mgi Jnum | J:283703 | Mgi Id | MGI:6386926 |
| Doi | 10.1016/j.canlet.2019.12.013 | Citation | Shen L, et al. (2020) Legumain-deficient macrophages promote senescence of tumor cells by sustaining JAK1/STAT1 activation. Cancer Lett 472:40-49 |
| abstractText | Macrophages serve as the first line of communication between tumors and the rest of the immune system, and understanding the interplay between macrophage and tumor cells is essential for developing novel macrophage-based strategy against tumor. Here, we show that deletion of legumain in macrophages activates senescence of tumor cells. Macrophage derived IL-1beta mediates the pro-senescent effect of Lgmn(-/-) macrophages since blockage of IL-1beta reverses the senescence phenotype in both a coculture model of macrophage and tumor cells and an orthotopic mouse model of breast cancer. Sustained activation of JAK1/STAT1 signaling and increased iNOS were found in the tumor cell-cocultured Lgmn(-/-) macrophages, which were necessary for IL-1beta expression and secretion. Applying a specific STAT1 agonist mimics the inductive effect of legumain deletion on IL-1beta expression in macrophages, and the effect can be blocked via inhibition of iNOS. Legumain and integrin alphavbeta3 interact to prevent STAT1 signaling in macrophages, and blockage of integrin alphavbeta3 stimulates STAT1 activation. Therapeutically, transplantation of bone marrow from Lgmn(-/-) mice suppresses the malignant growth of tumor by upregulating tumor cell senescence. Therefore, our finding highlights legumain in macrophages as a potential therapeutic target for tumors. |
